{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:17:22Z","timestamp":1776867442556,"version":"3.51.2"},"reference-count":37,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001849","name":"Defence Research and Development Organization","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001849","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.vaccine.2016.08.034","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T16:38:52Z","timestamp":1473439132000},"page":"5376-5383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Development of recombinant vaccine candidate molecule against Shigella infection"],"prefix":"10.1016","volume":"34","author":[{"given":"S.T.S.","family":"Chitradevi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Sivaramakrishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.08.034_b0005","first-page":"454","article-title":"Shigellosis: challenges & management issues","volume":"120","author":"Sur","year":"2004","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2016.08.034_b0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the global enteric multicenter study, GEMS): a prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2016.08.034_b0015","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the global enteric multicenter study (GEMS) inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.034_b0020","first-page":"1","article-title":"The growing problem of antimicrobial resistance among enteric pathogens","volume":"6","author":"Taylor","year":"2003","journal-title":"Clin Updates Infect Diseas"},{"key":"10.1016\/j.vaccine.2016.08.034_b0025","unstructured":"WHO Initiative for Vaccine Research (IVR); 2006."},{"key":"10.1016\/j.vaccine.2016.08.034_b0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/QCO.0b013e3282f88b92","article-title":"Shigellosis: the current status of vaccine development","volume":"21","author":"Kweon","year":"2008","journal-title":"Curr Opin Infect Diseas"},{"key":"10.1016\/j.vaccine.2016.08.034_b0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrgastro.2013.12","article-title":"Progress and pitfalls in Shigella vaccine research","volume":"10","author":"Barry","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0040","first-page":"113","article-title":"An update on vaccines against Shigella","volume":"1","author":"Ashkenazi","year":"2013","journal-title":"Ther Adv"},{"key":"10.1016\/j.vaccine.2016.08.034_b0045","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1128\/jb.175.18.5899-5906.1993","article-title":"Nonpolar mutagenesis of the ipa genes defines IpaB, IpaC and IpaD as effectors of Shigella flexneri entry into epithelial cells","volume":"175","author":"Menard","year":"1993","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0050","doi-asserted-by":"crossref","first-page":"G319","DOI":"10.1152\/ajpgi.2001.280.3.G319","article-title":"Microbes and microbial toxins: paradigms for microbial-mucosal interactions III. Shigellosis: from symptoms to molecular pathogenesis","volume":"280","author":"Sansonetti","year":"2001","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.femsre.2003.07.002","article-title":"Shigella flexneri infection: pathogenesis and vaccine development","volume":"28","author":"Jennison","year":"2004","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2016.08.034_b0060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/IAI.53.1.57-63.1986","article-title":"Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp","volume":"53","author":"Oaks","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0065","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/IAI.55.11.2681-2688.1987","article-title":"Entry of Shigella flexneri into Hela cells: evidence for directed phagocytosis involving actin polymerization and myosin accumulation","volume":"55","author":"Clerc","year":"1987","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0070","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1128\/iai.65.2.787-793.1997","article-title":"IpaB, a Shigella flexneri invasin, colocalizes with Interleukin-1\u03b2-converting enzyme in the cytoplasm of macrophages","volume":"65","author":"Thirumalai","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0075","doi-asserted-by":"crossref","first-page":"32895","DOI":"10.1074\/jbc.273.49.32895","article-title":"Shigella- induced apoptosis is dependent on caspase-1 which binds to IpaB","volume":"273","author":"Hilbi","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2016.08.034_b0080","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1128\/JB.183.4.1269-1276.2001","article-title":"Structure-function analysis of the Shigella virulence factor IpaB","volume":"183","author":"Guichon","year":"2001","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0085","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/IAI.06174-11","article-title":"Broadly protective Shigella vaccine based on type III secretion apparatus proteins","volume":"80","author":"Martinez-Becerra","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0090","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1016\/j.vaccine.2013.04.045","article-title":"Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD","volume":"31","author":"Heine","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.034_b0095","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1128\/IAI.00859-13","article-title":"Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine","volume":"81","author":"Martinez-Becerra","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0100","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.4049\/jimmunol.1302743","article-title":"Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes","volume":"192","author":"Heine","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/icb.2015.56","article-title":"A novel protein-based subunit Shigella vaccine candidate","volume":"93","author":"Venkatesan","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0110","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/icb.2015.24","article-title":"Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice","volume":"93","author":"Heine","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0167-5699(90)90050-J","article-title":"Heat shock proteins and the immune response","volume":"11","author":"Kaufmann","year":"1990","journal-title":"Immunol Today"},{"key":"10.1016\/j.vaccine.2016.08.034_b0120","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.vaccine.2013.02.045","article-title":"Recombinant heat shock protein 60 (Hsp60\/GroEL) of Salmonella enterica serovar Typhi elicits cross-protection against multiple bacterial pathogens in mice","volume":"31","author":"Chitradevi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.034_b0125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.drudis.2006.04.016","article-title":"Heat shock proteins as vaccine adjuvants in infections and cancer","volume":"11","author":"Segal","year":"2006","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.vaccine.2016.08.034_b0130","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/iai.56.11.2933-2941.1988","article-title":"Shigella flexneri invasion plasmid antigens B and C: epitope location and characterization with monoclonal antibodies","volume":"56","author":"Mills","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0135","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1128\/iai.61.9.3825-3831.1993","article-title":"Characterization of B-Cell epitopes on IpaB, an invasion-associated antigen of Shigella flexneri: identification of an immunodominant domain recognized during natural Infection","volume":"61","author":"Barzu","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0140","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/IAI.00470-10","article-title":"Domains of the Shigella flexneri type III secretion system IpaB protein involved in secretion regulation","volume":"78","author":"Shen","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0145","first-page":"1","article-title":"Co- administration of recombinant IpaB domain of Shigella flexneri with recombinant GroEL of Salmonella. Typhi enhances the immune responses and protective efficacy against lethal Shigella infection","author":"Chitradevi","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0150","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/iai.63.5.1947-1954.1995","article-title":"Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection","volume":"63","author":"Van de verg","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0155","series-title":"Oral tolerance: physiological basis and clinical applications. Mucosal Immunology","first-page":"587","author":"Mowat","year":"1999"},{"key":"10.1016\/j.vaccine.2016.08.034_b0160","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1128\/iai.63.5.2054-2061.1995","article-title":"Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in Shigellosis","volume":"63","author":"Islam","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0165","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1128\/IAI.66.4.1342-1348.1998","article-title":"An essential role for gamma interferon in innate resistance to Shigella flexneri infection","volume":"66","author":"Way","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.034_b0170","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4049\/jimmunol.164.4.2221","article-title":"Production of IFN-g and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain","volume":"164","author":"Samandari","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0175","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4049\/jimmunol.156.2.873","article-title":"Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24","volume":"156","author":"Suzue","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0180","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.4049\/jimmunol.0900978","article-title":"Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity","volume":"184","author":"Sellge","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.08.034_b0185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF02867548","article-title":"New age adjuvants and delivery systems for subunit vaccines","volume":"15","author":"Kurella","year":"2000","journal-title":"Indian J Clin Biochem"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1630706X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1630706X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T01:40:13Z","timestamp":1692495613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1630706X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":37,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0264410X1630706X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of recombinant vaccine candidate molecule against Shigella infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}